Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Serum Eye Drops for Ocular Surface Diseases
NCT07014059Phase 2Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Autologous serum eye drops 20% in graft-versus-host disease (GVHD), meibomian gland dysfunction (MGD), Stevens-Johnson syndrome (SJS) and 5 more. Primary endpoint: Feasibility of using the collection device under testing at 2 years. Started Jun 2025; status: active, not recruiting.
02
Drugs
Autologous serum eye drops 20%
03
Conditions
graft-versus-host disease (GVHD)meibomian gland dysfunction (MGD)Stevens-Johnson syndrome (SJS)Keratoconjunctivitis (KC)Persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT07014059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014059.